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The anti-emetic efficacy and tolerability of 5-hydroxytryptamine
(serotonin)3 antagonists, dopamine D2 receptor antagonists and
steroids have been studied in patients receiving moderately emeto-
genic chemotherapy. Though patients receive multiple cycles of
chemotherapy, the vast majority of these trials included only
patients during the initial one or two cycles of chemotherapy.
Corticosteroids alone or combined with other anti-emetics are
often used in the treatment of nausea and vomiting induced by
moderately emetogenic chemotherapy. Most trials have used
dexamethasone, whereas methylprednisolone and prednisolone
have been used less frequently, but there is no evidence that differ-
ences in efficacy or toxicity exist between different corticosteroids
(Cersosimo and Karp, 1986). The optimum dose and schedule of
steroids has not yet been defined (Aapro, 1991). As single agents,
corticosteroids are superior to placebo (Pollera et al, 1989) and
equal or superior to metoclopramide during the first cycle of
moderately emetogenic chemotherapy (Markman et al, 1984;
Ibrahim et al, 1986; Roila et al, 1988). The combination of dexa-
methasone and a dopamine D2 antagonist is also an effective and
widely used anti-emetic regimen in moderately emetogenic
chemotherapy. Metopimazine is a dopamine D2 antagonist with
anti-emetic activity superior to placebo (Moertel and Reitemeier,
1973; Israel and Rodary, 1978) and equal to prochlorperazine
(Moertel and Reitemeier, 1973) when given in oral doses of 10–
15 mg three times a day. Metopimazine is safe in oral doses of
30 mg four times a day (Herrstedt et al, 1997) and the anti-emetic
effect seems to be increased in high doses (Israel and Rodary,
1978; Vallejo et al, 1988; Clavel et al, 1993). In contrast to other
dopamine D2 antagonists metopimazine has no extrapyramidal
side-effects (Vallejo et al, 1988; Herrstedt et al, 1997).
The serotonin antagonist ondansetron is superior or equal to
metoclopramide during the initial one or two cycles of moderately
emetogenic chemotherapy (Bonneterre et al, 1990; Kassa et al,
1990; Marschner et al, 1991) but it is still debated if the anti-
emetic efficacy of the serotonin antagonists exceeds that of the
corticosteroids (Jones et al, 1991; Italian Group for Antiemetic
Research, 1995b). The efficacy of the serotonin antagonists
ondansetron, granisetron and tropisetron has been compared in
several trials and no significant differences have been shown
(Campora et al, 1994; Gebbia et al, 1994; Stewart et al, 1995).
The efficacy of anti-emetic treatment during multiple cycles of
moderately emetogenic chemotherapy has only been evaluated in
few trials and is not fully elucidated. Conclusions are not concor-
dant as different methodology and different statistical analyses
have been used. Some studies demonstrated a decrease in anti-
emetic efficacy (Martin et al, 1992; Soukop et al, 1992) whereas
others found sustained efficacy (Blijham, 1992; de Wet et al, 1993;
Kaizer et al, 1994; Italian Group for Antiemetic Research, 1995a;
Silva et al, 1996).
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Summary This randomized, double-blind, double-dummy parallel study compared the anti-emetic efficacy and tolerability of the serotonin
antagonist granisetron with prednisolone plus the dopamine D2 antagonist metopimazine during nine cycles of moderately emetogenic
chemotherapy. Chemotherapy naive women with stage I or II breast cancer scheduled to intravenous cyclophosphamide, fluorouracil and
methotrexate or cyclophosphamide, epirubicin and fluorouracil every 3 weeks were included. Patients received a single intravenous dose of
granisetron 3 mg or a 3-day oral treatment with prednisolone 25 mg once a day plus metopimazine 30 mg four times a day. A total of 223
women were enrolled and 218 patients (97.8%) were evaluable for efficacy. Granisetron (n = 109) was superior to prednisolone plus
metopimazine (n = 109) in the prophylaxis of acute nausea and vomiting during the first cycle of chemotherapy (P < 0.001) and prednisolone
plus metopimazine was superior on days 2–5 (P = 0.002). Overall, granisetron was superior on days 1–5 (P = 0.009). The median number of
cycles completed with granisetron was five (95% confidence interval 4–6) compared with two (95% confidence interval 2–2) for prednisolone
plus metopimazine (P = 0.0019). Constipation and rash were reported more frequently with granisetron (P < 0.001 and P = 0.043 respectively)
and palpitations more frequently with prednisolone plus metopimazine (P = 0.015). In conclusion, the number of cycles completed with
granisetron was significantly higher than the number completed with prednisolone plus metopimazine, but the anti-emetic efficacy of both
treatments declined during multiple cycles of moderately emetogenic chemotherapy.
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Cyclophosphamide-containing chemotherapy during multiple
cycles is widely used as adjuvant treatment in patients with breast
cancer (Early Breast Cancer Trialists’ Collaborative Group, 1992).
The efficacy and tolerability of anti-emetic treatment during a
standard regimen of nine courses of adjuvant cyclophosphamide-
based chemotherapy has not previously been investigated. This
randomized, double-blind study compares the anti-emetic activity
and tolerability of granisetron with the combination of pred-
nisolone plus metopimazine during nine courses of cyclophos-
phamide-based chemotherapy.
PATIENTS AND METHODS
Patients
Women with histologically confirmed stage I or II breast cancer
scheduled for nine cycles of adjuvant chemotherapy were eligible.
Other inclusion criteria were age between 18 and 70 years and
a performance status of 0–2 according to WHO criteria (World
Health Organization, 1979). Exclusion criteria were prior
chemotherapy, a peptic ulcer or diabetes, gastrointestinal obstruc-
tion, nausea or vomiting within 24 h before the first cycle of
chemotherapy and anti-emetic therapy (including steroids) during
the week before entry. The use of benzodiazepines for night-time
sedation was allowed.
Chemotherapy
Chemotherapy consisted of cyclophosphamide 600 mg m–2,
methotrexate 40 mg m–2 and fluorouracil 600 mg m–2 (CMF), or
cyclophosphamide 600 mg m–2, epirubicin 60 mg m–2 and fluoro-
uracil 600 mg m–2 (CEF) given intravenously every 3 weeks and
planned for nine cycles. Patients treated with radiotherapy to the
chest wall and axillary lymph nodes received cyclophosphamide
850 mg m–2 during that period (usually cycles 2 and 3).
Design of the study
A randomized, double-blind, placebo-controlled (double-dummy)
parallel design was used. Patients were randomized in blocks of
ten and stratified for centre and chemotherapy (CMF or CEF).
Anti-emetic treatment
Patients were randomly assigned to a single intravenous dose of
granisetron 3 mg (or placebo) diluted in 100 ml of saline given as a
5–15 min infusion starting 15 min before chemotherapy, or a 3-day
oral treatment with prednisolone 25 mg once a day plus metopi-
mazine 30 mg four times a day. The first dose of prednisolone and
metopimazine (or identical-appearing placebo tablets) was given
30 min before the start of chemotherapy, the second dose of
metopimazine (or placebo) 30 min before dinner, and the third just
before bedtime. On days 2 and 3, metopimazine (or placebo) was
taken 30 min before breakfast, lunch and dinner and just before the
patient went to bed. Prednisolone (or placebo) was administered
together with the first dose of metopimazine (or placebo). The
study medication was given in a plastic container with a separate
compartment for each dose. The container was returned at the next
chemotherapy cycle and the number of unused study tablets
counted. If, for any reason, the patients did not take all the tablets,
they were asked to explain the reasons on their diary card.
Assessment of anti-emetic efficacy
Following chemotherapy, patients recorded on days 1–5 on the
diary cards the number of vomiting episodes and dry retches, and
the severity of nausea and other adverse events. Any vomit
productive of liquid or a dry retch was considered a single emetic
episode. The severity of nausea and other adverse events were
assessed on a graded scale as: ‘none’, ‘mild’, ‘moderate’, or
‘severe’. Complete response (CR) was defined as no emetic
episodes and no nausea or only mild nausea; major response (MR)
as one emetic episode and/or moderate to severe nausea; minor
response (mR) as two to four emetic episodes, and failure as five
or more emetic episodes.
On the diary card day 5 after each cycle of chemotherapy,
patients were instructed to tick off one of the following two possi-
bilities: ‘I have been satisfied with the anti-emetic treatment and
want to continue with the same anti-emetic treatment during the
next cycle of chemotherapy’ or ‘I have not been satisfied with the
anti-emetic treatment and want another anti-emetic treatment
during the next cycle’.
During cycles 1 and 2, and thereafter only when necessary, a
research nurse called patients on days 2 and 5 to ensure that the
study medication was taken and the diary cards completed. To
assess the frequency of anticipatory nausea and vomiting, patients
were again called 3 days before the next cycle of chemotherapy
and reminded to record the number of vomiting episodes and dry
retches, and grade nausea on days 1–3 before the next course. The
diary card was returned at the following visit.
Patients were withdrawn from the study if they had had five or
more emetic episodes on one or more days during the study period,
or if they had ticked off on the diary card that they were not satisfied
with the anti-emetic treatment. Patients receiving rescue medication
were also withdrawn. If chemotherapy was changed, e.g. because of
progressive disease, the patients were also withdrawn.
Ethical considerations
The study was conducted according to the Helsinki II Declaration
and was approved by the local Scientific Ethics Committees and
by the Danish Medical Health Authorities. Written informed
consent was mandatory.
Table 1 Patient characteristics (n = 223)
No. of patients (%)
Granisetron Prednisolone plus
metopimazine
No. of patients 112 111
Age (years)
Median 47 46
Range 26–68 33–69
Performance status
0 109 108
13 3
20 0
Chemotherapy
Cyclophosphamide, methotrexate and
fluorouracil 101 (90.2) 102 (91.9)
Cyclophosphamide, epirubicin and
fluorouracil 11 (9.8) 9 (8.1)414 T Sigsgaard et al
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Statistical analysis
The number of patients to be enrolled in the trial was calculated on
the assumption that CR or MR on day 1 during the first cycle of
chemotherapy would be achieved in 60% of patients with pred-
nisolone plus metopimazine, and in 80% of those treated with
granisetron. Using a two-sided, 5% level test and a power of 0.8 it
was estimated that 91 evaluable patients in each treatment arm was
required. We therefore decided to include 220 patients.
The Mann–Whitney U-test was used to compare the number of
patients obtaining CR, MR, mR and failure on day 1 (acute), days
2–5 (delayed) and days 1–5 (overall) in cycle 1. For days 2–5 and
days 1–5 the analyses were based on the severity of nausea
recorded on the worst day within the period and, for emesis both
on the number of emetic episodes on the worst day in the period
and on the total number of emetic episodes in the period.
Maintenance of emetic control during cycles 1–9 (not failure,
satisfied with the anti-emetic treatment, and no rescue medication)
was calculated by the Kaplan–Meier method (cumulative emetic
control) and compared with the log-rank test. Patients going off
study due to other reasons were regarded as censored. The number
of completed cycles was compared with the log-rank test. The
maintenance of emetic control was also calculated based on condi-
tional probabilites (De Wit et al, 1996). The condition was that
failure of anti-emetic treatment did not occur in the previous
cycles.
The number and severity of side-effects were analysed with the
Mann–Whitney U-test. The number of patients with a rash was
compared with Fisher’s exact test. All tests were two-tailed using a
5% level of significance.
RESULTS
In all, 223 consecutive patients were included. A total of 112
patients received granisetron, and 111 received prednisolone plus
metopimazine. Patient characteristics are shown in Table 1. Five
patients were not eligible because they used benzodiazepines
during the daytime, leaving 218 patients evaluable for response in
cycle 1.
The results below represent these 218 evaluable patients and do
not differ from those obtained in the intention-to-treat analysis of
all 223 patients.
In the granisetron group 31, and in the prednisolone plus
metopimazine group 32, patients received cyclophosphamide
alone during the cycles with concomitant radiotherapy.
Table 2 shows the number of patients ‘at risk’ and the number
withdrawn at each cycle of chemotherapy. Fourteen patients went
off study during cycles 1–9 due to concomitant medication
with benzodiazepines (one) or steroids (one), termination of
chemotherapy before cycle 9 (four), toxicity, especially allergic
skin rashes (six) and incorrect study medication (two). The
number of cycles evaluable for nausea and vomiting were 514 in
the granisetron arm, and 384 in the prednisolone plus meto-
pimazine arm. A reduction in the dose of chemotherapy during
cycles 2–9 was performed in 50 (9.7%) cycles in the granisetron
group and 37 (9.6%) cycles in the prednisolone plus metopimazine
group. Dose reduction was 50% in all but three cycles. All tablets
were used in 460 (89.5%) and in 342 (89.1%) of the courses when
receiving granisetron, or prednisolone plus metopimazine, respec-
tively. Patients forgot one or more tablets during 32 (6.2%) cycles
with granisetron and during 32 (8.3%) cycles with prednisolone
plus metopimazine. In 19 (3.7%) and 10 (2.6%) cycles patients
were unable to take all tablets because of nausea and vomiting.
Efficacy of anti-emetic treatment cycle 1
Table 3 shows the response on day 1, days 2–5 and days 1–5.
Granisetron was significantly superior to prednisolone plus
metopimazine on day 1 (P < 0.001) with CR achieved in 75 of the
109 patients (68.8%) compared with 41 of the 109 patients
receiving prednisolone plus metopimazine (37.6%).
Among the 218 evaluable patients, six receiving granisetron and
34 prednisolone plus metopimazine were failures on day 1. Of
these, one (granisetron) and 16 (prednisolone plus metopimazine)
Table 2 Off study reasons, cumulative protection rates and conditional protection rates among 218 patients receiving adjuvant chemotherapy and treated with
granisetron or prednisolone plus metopimazine during cycles 1–9
Cycle number
1 2 3 4 5 6 7 8 9 All cycles
Total no. of patients 218 155 118 98 83 68 57 52 49
Granisetron
No. of patients 109 84 71 59 52 41 36 32 30
Failure 17 4 4 4 5 3 1 0 2 40
Not satisfied 8 6 5 3 4 1 2 1 0 30
Other reasonsa 033 0 211 1 01 1
Cumulative protection rates 0.77 0.68 0.59 0.52 0.43 0.39 0.36 0.35 0.32
Conditional protection rates 0.77 0.88 0.87 0.88 0.83 0.90 0.92 0.97 0.93
Prednisolone plus metopimazine
No. of patients 109 71 47 39 31 27 21 20 19
Failure 34 22 5 7 4 4 1 1 1 79
Not satisfied 3 2 1 1 0 2 0 0 0 9
Other reasonsa 102 0 000 0 03
Cumulative protection rates 0.66 0.44 0.38 0.30 0.26 0.21 0.20 0.19 0.18
Conditional protection rates 0.66 0.66 0.87 0.79 0.87 0.78 0.95 0.95 0.95
aThese included cessation of chemotherapy (four patients), concomitant medication with benzodiazepines or corticosteroids (four patients), or other reasons (six
patients).Anti-emetic treatment during multiple cycles of chemotherapy415
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went off study after day 1 and one granisetron patient was with-
drawn after day 1 as she was not satisfied with the anti-emetic
treatment. This means that 200 patients were evaluable on days
2–5; 107 in the granisetron group (of which five were failures on
day 1) and 93 in the prednisolone plus metopimazine group (of
which 18 were failures on day 1). In contrast to day 1, meto-
pimazine plus prednisolone was more effective than granisetron
on days 2–5 after chemotherapy. Of the patients with CR on day 1,
65.3% treated with granisetron and 85.4% treated with pred-
nisolone plus metopimazine, also had a CR on days 2–5 (P=
0.029). Among the patients without CR on day 1, 15.6% given
granisetron and 57.7% given the combination had CR on days 2–5
(P< 0.001). Based on the worst day in the period, CR was
observed in 54 of the 107 patients receiving granisetron (50.5%)
and in 65 of the 95 patients receiving the combination treatment
(69.9%) (P= 0.002, Table 3). Focusing on the overall response,
based on the worst day during days 1–5, granisetron was superior
to prednisolone plus metopimazine (P= 0.009).
Efficacy of anti-emetic treatments during multiple
cycles
The median number of cycles completed with granisetron was five
(95% confidence interval 4–6) compared with two (95% confi-
dence interval 2–2) for prednisolone plus metopimazine (P=
0.0019). The anti-emetic efficacy (cumulative emetic control) of
both treatments decreased from cycle 1 to cycle 9 as shown in
Figure 1. The number of evaluable patients starting each new
course of chemotherapy and the number of patients who were fail-
ures, who were not satisfied with the anti-emetic treatment, or who
went off study due to other reasons during the nine chemotherapy
courses, are given in Table 2. Of the 109 patients in each group,
only 28 (25.7%) in the granisetron group compared with 18
(16.5%) in the prednisolone plus metopimazine group completed
all nine courses with less than five emetic episodes on any day and
were still satisfied with the treatment. Forty patients (36.7%) were
failures in the granisetron group compared with 79 (72.3%) in
the other group. The number of patients who went off study
because they were not satisfied with the anti-emetic treatment
were 30 (27.5%, granisetron) and nine (8.3%, prednisolone plus
metopimazine).
Anticipatory nausea and vomiting during cycles 1–9
With granisetron and prednisolone plus metopimazine the number
of cycles evaluable for anticipatory nausea and vomiting was 466
and 336 respectively. CR on days 1–3 before the next cycle of
chemotherapy was observed in 456 cycles (97.9%) with
granisetron and 328 cycles (97.6%) with prednisolone plus
metopimazine. Data for anticipatory nausea and vomiting were
incomplete in three cycles in both regimens.
Table 3Anti-emetic response cycle 1 in 218 patients treated with granisetron or prednisolone plus metopimazine
No. of patients (%)
Granisetron Prednisolone plus P-valuea
metopimazine
Day 1 109 (100.0) 109 (100.0) <0.001
Complete 75 (68.8) 41 (37.6)
Major 18 (16.5) 21 (19.3)
Minor 10 (9.2) 13 (11.9)
Failure 6 (5.5) 34 (31.2)
Days 2–5b 107 (100.0) 93 (100.0) 0.002
Complete 54 (50.5) 65 (69.9)
Major 26 (24.3) 18 (19.4)
Minor 12 (11.2) 9 (9.7)
Failure 15 (14.0) 1 (1.1)
Days 1–5b 109 (100.0) 109 (100.0) 0.009
Complete 49 (45.0) 35 (32.1)
Major 26 (23.9) 24 (22.0)
Minor 17 (15.6) 16 (14.7)
Failure 17 (15.6) 34 (31.2)
aMann–Whitney U-test. bBased on the worst day in the period. Results based on the total number of emetic
episodes and the worst day of nausea in the period are similar.
1.00
0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
0123456789
Cycles of chemotherapy
GRA (n = 109)
PRED + MPZ
(n = 109)
P = 0.0019
(log-rank test)
Figure 1Maintenance of emetic control in patients with breast cancer
treated with granisetron or prednisolone plus metopimazine during nine
cycles of adjuvant chemotherapy. GRA = granisetron, PRED = prednisolone,
MPZ = metopimazine416 T Sigsgaard et al
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Safety
In all, 533 cycles with granisetron and 415 cycles with pred-
nisolone plus metopimazine were evaluable for adverse events.
These were generally mild to moderate in severity. Based on the
worst day during the total number of courses the most frequently
reported adverse events in the granisetron group and in the metopi-
mazine plus prednisolone group (% of patients) were headache
(40.2% vs 30.6%, P = 0.208), dizziness (16.1% vs 16.3%, P =
0.935), constipation (24.1% vs 2.7%, P < 0.001), palpitation (1.8%
vs 10.8%, P = 0.015) and rash (11.6% vs 3.6%, P = 0.043). Six
patients went off study due to side-effects: four treated with
granisetron and two treated with prednisolone plus metopimazine.
Among the four patients treated with granisetron, one had an
allergic reaction during the infusion of methotrexate in cycles 6
and 7, one had a rash and severe dyspnoea in cycle 3 on day 1, one
had a rash and mild dyspnoea in cycle 2 on day 2, and one had a
rash in cycle 3 on day 2. One patient treated with prednisolone plus
metopimazine went off study due to a rash in cycles 2 and 3, and
one due to influenza-like symptoms and severe headache in cycle
1 on day 1 and epigastric pain on days 2–5.
DISCUSSION
This is the first randomized, double-blind study to investigate anti-
emetic efficacy during nine cycles of moderately emetogenic
chemotherapy. Granisetron was superior to the combination of pred-
nisolone plus metopimazine in the treatment of acute nausea and
vomiting during the first cycle of chemotherapy. CR on day 1 was
obtained in 68.8% of the patients treated with granisetron
in accordance with the results in other trials investigating a
5-hydroxytryptamine3 (5-HT3) antagonist (Bonneterre et al, 1990;
Kaasa et al, 1990; Marty, 1990; Jones et al, 1991; Marschner et al,
1991; Warr et al, 1991; Italian Group for Antimetic Research, 1995b).
When the trial was initiated granisetron was available in
Denmark for intravenous use only. It has now been shown that a
single oral dose of 2 mg granisetron is as effective as intravenous
treatment with a serotonin antagonist (Perez et al, 1998).
The efficacy of a corticosteroid plus a dopamine D2 antagonist
in the prophylaxis of emesis from moderately emetogenic
chemotherapy has been verified in several trials. In comparison
with a 5-HT3 antagonist, such a combination equalled (Levitt et al,
1993) or was inferior (Marty, 1990; Warr et al, 1991) to the 5-HT3
antagonist. On the other hand, when the dose of the corticosteroid
was increased and the dose divided, the steroid was as effective as
a 5-HT3 antagonist (Marschner et al, 1991; Italian Group for
Antiemetic Research, 1995b). Only a few investigators have
addressed the importance of dose and schedule of steroids (Chiara
et al, 1987; Coleman et al, 1991; Gez et al, 1992; Havsteen and
Kjær, 1996) and the optimum dose and schedule is still unknown.
The comparative data, however, suggest that the efficacy of
steroids is optimized by divided doses.
Delayed emesis, initially observed after cisplatin, also occurs
after moderately emetogenic chemotherapy. Patients receiving non-
cisplatin chemotherapy are, however, not always treated for delayed
emesis (Marty, 1990; Italian Group for Antiemetic Research, 1995b;
Silva et al, 1996), as relatively good anti-emetic control is possible
during the days following chemotherapy without anti-emetic treat-
ment. Therefore, and because in Denmark granisetron was available
for intravenous treatment only when the study was initiated,
granisetron was given as a single intravenous dose.
Incomplete protection from acute nausea and vomiting is the
most important risk factor for delayed emesis after cisplatin (Roila
et al, 1991; Italian Group for Antiemetic Research, 1994).
However, in one trial, in-patient status was the only significant
risk factor for delayed emesis after moderately emetogenic
chemotherapy (Kaizer et al, 1994). We observed that a 3-day treat-
ment with prednisolone plus metopimazine was superior to a
single dose of granisetron in the treatment of delayed emesis in
cycle 1. Only one patient receiving the combination failed on days
2–5, even though 18 of the 93 patients evaluated for delayed
emesis were failures on day 1. In the granisetron group, six
patients were failures on day 1, and on days 2–5, 15 patients were
failures. Furthermore, among both patients with CR and patients
with non-complete response day 1 in the initial cycle the protec-
tion from delayed nausea and vomiting was significantly superior
with prednisolone plus metopimazine.
Our results indicate that the combination of a corticosteroid plus
a dopamine D2 antagonist is effective in the treatment of delayed
emesis following moderately emetogenic chemotherapy. This is in
accordance with other studies where low-dose metoclopramide
plus dexamethasone was more effective than either placebo (Kris
et al, 1989) or dexamethasone alone (Kris et al, 1989; Moreno et
al, 1992), dexamethasone plus prochlorpromazine more effective
than granisetron (Matsui et al, 1996), and alizapride more effective
than the 5-HT3 antagonist ondansetron (Münstedt et al, 1995) in
controlling delayed nausea and vomiting after cisplatin. After
cyclophosphamide-based chemotherapy dexamethasone alone is
effective (Koo and Ang, 1996). In trials evaluating the efficacy of
anti-emetic agents during multiple cycles of moderately emeto-
genic chemotherapy (non-cisplatin – Blijham, 1992; Martin et al,
1992; Soukop et al, 1992; Italian Group for Antiemetic Research,
1995a; Silva et al, 1996; non-cisplatin and cisplatin < 50 mg m–2 –
de Wet et al, 1993; Kaizer et al, 1994) several diversities in patient
population (Blijham, 1992; Martin et al, 1992; Soukop et al, 1992;
de Wet et al, 1993; Kaizer et al, 1994; Italian Group for Antiemetic
Research, 1995a; Silva et al, 1996), trial methodology (Blijham,
1992; Martin et al, 1992; Soukop et al, 1992; de Wet et al, 1993;
Kaizer et al, 1994; Italian Group for Antiemetic Research, 1995a;
Silva et al, 1996), or statistical analyses complicate the interpreta-
tion of results. Some authors include all patients in the evaluation
of anti-emetic effect during multiple cycles (Martin et al, 1992;
Soukop et al, 1992; Italian Group for Antiemetic Research, 1995a;
Silva et al, 1996), whereas others include only patients with ‘good’
anti-emetic response during the first cycle of chemotherapy (de
Wet et al, 1993; Kaizer et al, 1994) or only those who requested the
same anti-emetic treatment in the following cycles (Blijham,
1992). It has been stated that the Kaplan–Meier method should be
used for the calculation of the overall protection during multiple
cycles (De Wit et al, 1996). If calculations are based on conditional
probabilities of protection, only patients with protection in
previous cycles are included leading to an overestimation of the
sustainment of protection (De Wit et al, 1996). Using the
Kaplan–Meier method we found that the efficacy of both treat-
ments decreased during multiple cycles, but with the method of
conditional probabilities the efficacy increased (Table 2). Some
trials have reported sustained efficacy of anti-emetic treatment
during multiple cycles of moderately emetogenic chemotherapy
(Blijham, 1992; de Wet et al, 1993; Kaizer et al, 1994; Italian
Group for Antiemetic Research, 1995a; Silva et al, 1996), but in
three of these trials the investigators used the method of condi-
tional probabilities for the calculation (Blijham, 1992; de Wet et al,1993; Kaizer et al, 1994). In two of the studies the number of
patients still at risk decreased to less than 10% in cycles 8 and 10
respectively (Blijham, 1992; de Wet et al, 1993) and in the other
three (Kaizer et al, 1994; Italian Group for Antiemetic Research,
1995a; Silva et al, 1996) the efficacy was only evaluated during
the first three cycles. The trials reporting decreasing efficacy of
anti-emetic treatment during multiple cycles evaluated the efficacy
during six cycles of chemotherapy (Martin et al, 1992; Soukop et
al, 1992). As in our study, only women were included. Females
are at higher risk of developing nausea and vomiting after
chemotherapy than men (Tonato et al, 1991). The differences in
study design and statistical methods may explain the different
results when evaluating anti-emetic efficacy during multiple
cycles. To detect a decrease in efficacy of anti-emetic efficacy,
three cycles may be too few. The reason for this decrease of effi-
cacy during multiple cycles is unknown. Andrews et al have
demonstrated, in ferrets treated with radiotherapy, ‘plasticity and
modulation’ of the emetic pathway following vagotomy (Andrews
and Davis, 1993) and the decrease in anti-emetic efficacy during
multiple cycles might be explained by this ‘plasticity’ or reorgani-
zation in the emetic pathway.
Both treatments were generally well-tolerated. As in other
studies, constipation was more frequently reported with
granisetron. In previous trials, rash has rarely been reported with
granisetron (Adams and Valley, 1995). However, in this study 13%
of patients treated with granisetron reported rash. It is possible that
this was caused by granisetron or by concomitant medication
including chemotherapy. Many trials have only followed the
patients on day 1 during the initial cycle. Except for two patients in
our trial, rash was not reported during cycle 1, but during cycle 2
or the following cycles. With observation of patients for more than
one day and after cycle 1, rash may be reported more frequently.
The efficacy of granisetron and of prednisolone plus metopi-
mazine declined during nine cycles of CMF/CEF chemotherapy
and after completion of cycle 9 only 25.7% and 16.5% of patients,
respectively, were still at risk. This clearly emphasizes the need for
improvement of anti-emetic efficacy. A combination of both a 5-
HT3 antagonist, a steroid and a dopamine D2 antagonist might
further improve the control of nausea and vomiting induced by
moderately emetogenic chemotherapy. This is supported by inves-
tigations showing that the efficacy of a 5-HT3 antagonist is
improved by addition of a steroid (Italian Group for Antiemetic
Research, 1995b) and metopimazine (Herrstedt et al, 1993). Future
trials investigating the efficacy of a 5-HT3 antagonist in combina-
tion with either a steroid or a dopamine D2 antagonist or both
during multiple cycles of chemotherapy are warranted.
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